ADC Therapeutics (ADCT) Liabilities and Shareholders Equity (2019 - 2026)

ADC Therapeutics has disclosed Liabilities and Shareholders Equity across 8 years of filings, most recently posting $291.5 million for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $291.5 million, up 6.96% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.2 billion (down 6.8% YoY), and the FY2025 annual result was $323.2 million, changed 0.36% from the prior year.
• Liabilities and Shareholders Equity came in at $291.5 million for Q1 2026 at ADC Therapeutics, down from $323.2 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $490.9 million in Q4 2022 to a low of $272.5 million in Q1 2025.
• The 5-year median for Liabilities and Shareholders Equity is $322.0 million (2024), against an average of $335.9 million.
• Across the five-year window, Liabilities and Shareholders Equity dropped 27.72% in 2023 and gained 6.96% in 2026, its largest moves.
• ADC Therapeutics' Liabilities and Shareholders Equity stood at $490.9 million in 2022, then decreased by 27.72% to $354.8 million in 2023, then retreated by 9.25% to $322.0 million in 2024, then grew by 0.36% to $323.2 million in 2025, then dropped by 9.8% to $291.5 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $291.5 million (Q1 2026), $323.2 million (Q4 2025), and $289.8 million (Q3 2025), per Business Quant data.